Wesley Wang, Zeynep Temerit Kumm, Cindy Ho, Ideli Zanesco-Fontes, Gustavo Texiera, Rui Manuel Reis, Horacio Martinetto, Javaria Khan, Martin G McCandless, Katherine E Baker, Mark D Anderson, Muhammad Omar Chohan, Sasha Beyer, J Brad Elder, Pierre Giglio, José Javier Otero
BACKGROUND: Glioblastoma is a malignant brain tumor requiring careful clinical monitoring even after primary management. Personalized medicine has suggested the use of various molecular biomarkers as predictors of patient prognosis or factors utilized for clinical decision-making. However, the accessibility of such molecular testing poses a constraint for various institutes requiring identification of low-cost predictive biomarkers to ensure equitable care. METHODS: We collected retrospective data from patients seen at Ohio State University, University of Mississippi, Barretos Cancer Hospital (Brazil), and FLENI (Argentina) who were managed for glioblastoma-amounting to 581 patient records documented using REDCap...
2024: Neuro-oncology advances